Home>Topics>Funds>SPDR S&P Biotech

SPDR S&P Biotech

  1. All
  2. Commentary
  1. SPDR S&P Biotech

    Commentary

    Mon, 8 Dec 2014

    Can I buy this ETF ( XBI ) at Fidelity or Vanguard or are the commissions too high? Schwab or eTrade? Thanks in advance

  2. T/A May 2014 -- SPY "Home On The Range"

    Commentary

    Wed, 30 Apr 2014

    Some plays like XLI are still Bullish. Momentum stocks as represented by QQQ and XBI have broken down and are in a Bearish IT for now. My computer considers her XBI trade management as the “Greatest Escape Since Dunkirk” but she tends to be

  3. April T/A - Sell before May and go away?

    Commentary

    Fri, 28 Mar 2014

    fate of the bull market a little. Again, not enough evidence to pronounce it dead yet though. Speaking of Biotechs This is XBI , and it looks like a heck of a blow off top from where we sit today. I advocated buying if you were a bull yesterday; today

  4. From Barron’s, March 24, 2014 (Part 2)

    Commentary

    Sat, 22 Mar 2014

    bond funds. Pg 35: Biotechs are hot and the related ETFs [ IBB, XBI ] are attracting huge inflows [YTD inflows are already more than those for entire 2013]. The P/E of XBI is 33 excluding negative earnings and -19 [ yes, minus 19 ] after including

  5. Zacks.com

    Commentary

    Sat, 7 Dec 2013

    and two Small Cap ETFs came up also but the big category turned out to be HealthCare. IBB at 12.23%, BBH up 11.71% and XBI up 12.21% to name a few. I counted 12 ETFs up over 6% in the 1 Mon (%). I'm wondering if what I'm hearing in the

  6. From Barron’s, August 26, 2013 (Part 2)

    Commentary

    Sat, 24 Aug 2013

    KRE , insurance KIE , [financials were cutoff at the knees during the financial crisis and have many years to run], biotech XBI and IBB . The ETFs have a strong survivor bias – if something terrible happens with a component, it is replaced by something

Content Partners